(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Before trips to Mars, we need better protection from cosmic rays - 2Israel issues notice that Ben-Gurion Airport flights likely restricted until at least April 16
- 3Vote in favor of your Favored kind of pasta
- 4Somalia set for 'historic' first offshore oil drilling
- 5New Gaza militia declares war on Hamas: 'Your dirty shoes are more honorable'
- 4 well known subjects in school
- Foreign military officials can become Israel's ambassadors, senior IDF commander tells 'Post'
- Investigating the Advantages of a Bank account: A Complete Aide
- Well known Tea Brands for Each Tea Sweetheart
- 6 Fun Urban areas For Seniors To Travel
- Guns N' Roses 2026 Tour: How to get tickets, presale times, prices and more
- Finding the Universe of Craftsmanship: Individual Encounters in Imagination
- How Skoda Lost Its Biggest Market In Just Seven Years
- Old video misrepresented as senior Sri Lankan ruling party member criticising president over fuel shortage
